Remove Bacteria Remove Genomics Remove Reagent
article thumbnail

BioSpace Global Roundup: Ipsen Wins Fast Track Designation for Cancer Drug and More

The Pharma Data

aeruginosa bacteria, instead of killing the bacteria as an antibiotic would aim to do. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. Financial details of the agreement were not disclosed.

Drugs 52
article thumbnail

BioSpace Global Roundup, Oct. 15

The Pharma Data

ERS Genomics – Ireland’s ERS Genomics signed an agreement with FASMAC Co., Under the terms of the non-exclusive agreement FASMAC acquires the right to use CRISPR/Cas9 technology and commercialize tools and reagents associated with it. The patent is valid through 2038. Ltd of Japan.